Press Release Details

BEDFORD, Mass., January 3, 2019 – Stoke Therapeutics will present on its pioneering work to develop the first gene-specific, disease-modifying therapies for genetic epilepsies at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco next week.

Chief Executive Officer Ed Kaye, M.D., will share details on Stoke’s novel approach to upregulate gene expression with antisense oligonucleotide therapies. The technology, Targeted Augmentation of Nuclear Gene Output (TANGO), is designed to restore protein production to normal levels in patients with autosomal dominant disorders in which one copy of a gene is healthy and the other is dysfunctional.

Stoke’s lead indication is Dravet Syndrome, a rare and devastating form of genetic epilepsy that affects more than 35,000 patients in the U.S., the European Union and Japan. Dr. Kaye will present data showing that Stoke’s TANGO technology successfully increases production of the key protein missing in Dravet Syndrome, Nav1.1, in a highly precise, durable and controlled manner in mouse models. Stoke’s drug candidate would be the first therapy to address the root cause of Dravet Syndrome and modify the course of the disease.

Stoke is also advancing programs using TANGO in other disorders of the central nervous system as well as genetic diseases of the eye, liver and kidney.

Stoke’s presentation details:

Date: Tuesday, January 8, 2019
Time: 10 – 10:25 a.m. PST
Location: Westin St. Francis Hotel, Elizabethan Room D

About Stoke Therapeutics 
Stoke Therapeutics is a biotechnology company working to increase gene expression to treat a wide array of severe genetic diseases, including genetic conditions affecting the central nervous system, eye and liver. Stoke was launched in 2018 with a $40 million Series A investment funded by Apple Tree Partners. For more information visit www.stoketherapeutics.com and follow Stoke on Twitter @StokeTx.

Media Contact 
Sara Green
Ten Bridge Communications
sgreen@tenbridgecommunications.com
617-233-1714